Richard Barfield, chief financial officer of Ergomed PLC (AIM:ERGO, ETR:2EM) talks to Proactive London about the company's expectations-exceeding results.
He points a lot of the success to "significant tailwinds" in specialist sectors, such as oncology and rare disease, pharmacovigilance and general pharmaceutical.
Barfield also discusses organic growth, with further acquisitions targeted in the US and Asian markets.